Update on spondyloarthropathies

Annals of Internal Medicine

Volumn 136, Issue 12, 2002, Pages 896-907

  Khan, Muhammad Asim ^a  

^a METROHEALTH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; ETANERCEPT; HLA B27 ANTIGEN; HLA C ANTIGEN; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANKYLOSING SPONDYLITIS; CHLAMYDIASIS; CHROMOSOME 6P; CHRONIC INFLAMMATION; CLINICAL TRIAL; CROHN DISEASE; DISEASE COURSE; ENTEROBACTER INFECTION; ENVIRONMENTAL FACTOR; GENE LOCUS; GENETIC PREDISPOSITION; HUMAN; PATHOGENESIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; REACTIVE ARTHRITIS; REVIEW; RHEUMATIC DISEASE; SOMNOLENCE; SPONDYLOARTHROPATHY; TERATOGENICITY; ULCERATIVE COLITIS;

EID: 0037129952     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-136-12-200206180-00011     Document Type: Review

References (143)

1. Ankylosing spondylitis
2. Spondylarthopathies
3. Association between ankylosing spondylitis, psoriatic arthritis, Reiter's disease, the intestinal arthropathies, and Behcet's syndrome
4. Spondyloarthropathies
5. A wider spectrum of spondyloarthropathies
6. Undifferentiated spondyloarthropathies
7. Ankylosing spondylitis and undifferentiated spondyloarthropathies: A clinical review and description of a disease subset with older age at onset
8. Histopathologic evidence that sacroiliitis in ankylosing spondylitis is not merely enthesitis
9. Enthesitis and ankylosis in spondyloarthropathy: What is the target of the immune response?
10. Entheses and enthesitis: A histopathologic review and relevance to spondyloarthritides
11. Enthesitis in spondyloarthropathy
12. The anatomical basis of disease localization in seronegative spondyloarthropathy at entheses and related sites
13. Immunohistological study of entheses in spondyloarthropathies: Comparison in rheumatoid arthritis and osteoarthritis
14. Radiologic diagnosis and pathology of the spondyloarthropathies
15. Ankylosing spondylitis - At the interface of bone and cartilage
16. Jekyll and Hyde: The transformation of HLA-B27
17. Ankylosing spondylitis and HL-A 27
18. HLA-B27 and its subtypes in world populations [Editorial]
19. HLA class I associations of ankylosing spondylitis in the white population in the United Kingdom
20. Association of MHC class I with spondyloarthropathies in Kuwait
21. Profile of Reiter's disease in Saudi Arabia
22. Diagnostic value of HLA-B27 testing ankylosing spondylitis and Reiter's syndrome
23. Ankylosing spondylitis: Clinical features
24. Spondyloarthropathy in the community: Clinical syndromes and disease manifestations in Alaskan Eskimo populations
25. Can some cases of 'possible' spondyloarthropathy be classified as 'definite' or 'undifferentiated' spondyloarthropathy? Value of criteria for spondyloarthropathies
26. Evaluation of the Amor and ESSG classification criteria for spondylarthropathies in a Turkish population
27. Spondyloarthropathies in Japan: Nationwide questionnaire survey performed by the Japan Ankylosing Spondylitis Society
28. Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Tromso, northern Norway
29. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors
30. Prevalence of rheumatoid arthritis and spondyloarthropathy in Brittany, France
31. Eye involvement in the spondyloarthropathies
32. Undiagnosed spondyloarthropathy in patients presenting with anterior uveitis
33. Cardiac manifestations in patients with HLA B27-associated juvenile arthritis
34. Aneurysmal dilatation of ascending aorta and aortic insufficiency in juvenile spondyloarthropathy
35. Aortic root disease and valve disease associated with ankylosing spondylitis
36. HLA-B27-associated cardiac disease
37. Diagnosis of ankylosing spondylitis
38. Atypical clinical presentation of ankylosing spondylitis
39. Evaluation of patients with back pain of suspected inflammatory nature
40. Spondylitic disease without radiologic evidence of sacroiliitis in relatives of HLA-B27 positive ankylosing spondylitis patients
41. Chest pain without radiographic sacroiliitis in relatives of patients with ankylosing spondylitis
42. Chest pain - A common feature of ankylosing spondylitis
43. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria
44. Magnetic resonance imaging of sacroiliac joint inflammation
45. Use of dynamic magnetic resonance imaging to detect sacroiliitis in HLA-B27 positive and negative children with juvenile arthritides
46. Delay in diagnosis of spondarthritis
47. A comparison of patients with spondyloarthropathy seen in specialty clinics with those identified in a community wide epidemiologic study. Has the classic case misled us?
48. Scientific contributions of ankylosing spondylitis patient advocacy groups
49. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis
50. Comparison of clinical features in HLA-B27 positive and negative patients with ankylosing spondylitis
51. Significant loss of bone mass in patients with early, active ankylosing spondylitis: A follow-up study
52. Relationship between disease activity and serum levels of vitamin D metabolites and parathyroid hormone in ankylosing spondylitis
53. The prevalence of vertebral fractures in mild ankylosing spondylitis and their relationship to bone mineral density
54. Traumatic spinal cord injury complicating ankylosing spondylitis
55. Occult vertebral fractures in ankylosing spondylitis
56. Focal spinal abnormalities on bone scans in ankylosing spondylitis: A clue to the presence of fracture or pseudarthrosis
57. Spinal fractures and pseudoarthrosis complicating ankylosing spondylitis: MRI manifestation and clinical significance
58. Reiter's syndrome and reactive arthritis: A current view
59. Reactive arthritis
60. Diagnosing reactive arthritis: Role of clinical setting in the value of serologic and microbiologic assays
61. Chlamydia and associated arthritis
62. Reiter's syndrome. Diagnosis and clinical features
63. The cutting edge of spondyloarthropathy research in the millennium
64. Bacillus Calmette-Guérin associated arthropathy mimicking undifferentiated spondyloarthropathy
65. Bacillus Calmette-Guérin induced reactive arthritis
66. Chlamydia pneumoniae as a triggering infection in reactive arthritis
67. Persistent or severe course of reactive arthritis following Salmonella enteritidis infection. A prospective study of 9 cases
68. The co-occurrence of Reiter's syndrome and acquired immunodeficiency
69. Psoriatic arthritis and the spectrum of syndromes related to the SAPHO (synovitis, acne, pustulosis, hyperostosis, and osteitis) syndrome
70. Psoriatic arthritis and human immunodeficiency virus infection in Zambia
71. Spondyloarthropathies in sub-Saharan Africa
72. Psoriatic arthritis
73. Generic studies of psoriatic arthritis: Dissecting joints and skin
74. The genetics of psoriasis: A complex disorder of the skin and immune system
75. Psoriatic arthritis: Clinical aspects, genetics, and the role of T cells
76. Spondyloarthropathy is underestimated in inflammatory bowel disease: Prevalence and HLA association
77. Subclinical sacroiliitis in inflammatory bowel disease: A clinical and follow-up study
78. Inflammatory bowel disease and spondyloarthropathy
79. Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis-cellularity correlates with the degree of enhancement detected by magnetic resonance imaging
80. Classification of inflammatory arthritis by enthesitis
81. HLA molecules, bacteria and autoimmunity
82. Inflammatory disease in HLA-B27 transgenic rats
83. HLA-B27 and other predisposing factors in spondyloarthropathies
84. Human leukocyte subpopulations from inflamed gut bind to joint vasculature using distinct sets of adhesion molecules
85. CD8(+) T-cell autoreactivity to an HLA-B27-restricted self-epitope correlates with ankylosing spondylitis
86. The histopathology of ankylosing spondylitis: Are there unifying hypotheses?
87. CD4+ and CD8+ clonal T cell expansions indicate a role of antigens in ankylosing spondylitis; a study in HLA-B27+ monozygotic twins
88. The aetiology of psoriatic arthritis
89. Susceptibility to ankylosing spondylitis in twins: The role of genes, HLA, and the environment
90. HLA-B27 and genetic predisposing factors in spondyloarthropathies
91. HLA-B27 and immunogenetics of spondyloarthropathies
92. HLA-B27 alone rather than B27-related class I haplotypes contributes to ankylosing spondylitis susceptibility
93. Whole-genome screening in ankylosing spondylitis: Evidence of non-MHC genetic-susceptibility loci
94. The familial form of spondylarthropathy: A clinical study of 115 multiplex families
95. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease
96. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease
97. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations
98. Localization of psoriasis-susceptibility locus PSORS1 to a 60-kb interval telomeric to HLA-C
99. HLA-B27 presents a peptide from a polymorphic region of its own molecule with homology to proteins from arthritogenic bacteria
100. HLA-B27 misfolding and spondyloarthropathies: Not so groovy after all?
101. A hypothesis for the HLA-B27 immune dysregulation in spondyloarthropathy: Contributions from enteric organisms, B27 structure, peptides bound by B27, and convergent evolution
102. HLA-B27 polymorphism
103. HLA-B27 polymorphism and association with disease
104. HLA-B27 subtypes positively and negatively associated with spondyloarthropathy
105. The HLA-B*2709 subtype confers susceptibility to spondyloarthropathy
106. Management of spondyloarthropathy
107. Ankylosing spondylitis
108. Conventional therapies for ankylosing spondylitis
109. The role of passive stretching in the treatment of ankylosing spondylitis
110. Continuation of group physical therapy is necessary in ankylosing spondylitis: Results of a randomized controlled trial
111. The effects of comprehensive home physiotherapy and supervision on patients with ankylosing spondylitis - A randomized controlled trial
112. Cost effectiveness of group physical therapy compared to individualized therapy for ankylosing spondylitis. A randomized controlled trial
113. Evidence suggesting that health education for self-management in patients with chronic arthritis has sustained health benefits while reducing health care costs
114. What counselling do patients with ankylosing spondylitis receive? Results of a questionnaire survey
115. Traumatic spinal cord injury as a complication to ankylosing spondylitis. An extended report
116. Methotrexate in severe ankylosing spondylitis: A randomized placebo controlled, double-blind observer study
117. Low dose amitriptyline in ankylosing spondylitis: A short term, double blind, placebo controlled study
118. Early antibiotic treatment of reactive arthritis associated with enteric infections: Clinical and serological study
119. Effect of antimicrobial treatment on chronic reactive arthritis
120. No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis: A three-month, multicenter, double-blind, randomized, placebo-controlled study
121. Ciprofloxacin treatment does not influence course or relapse rate of reactive arthritis and anterior uveitis
122. Doubleblind, placebo-controlled study of three-month treatment with lymecycline in reactive arthritis, with special reference to Chlamydia arthritis
123. Antibiotic treatment of venereal disease and Reiter's syndrome in a Greenland population
124. New treatment options in spondyloarthropathies: Increasing evidence for significant efficacy of anti-tumor necrosis factor therapy
125. Treatment of active ankylosing spondylitis with infliximab: A randomized controlled multicenter trial
126. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab
127. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondyloarthropathy
128. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial
129. TNF alpha inhibition in psoriatic arthritis: Cause for hope
130. Etanercept in children with polyarticular juvenile rheumatoid arthritis
131. Which domains should be included in a core set for endpoints in ankylosing spondylitis? Introduction to the ankylosing spondylitis module of OMERACT IV
132. Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis
133. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha
134. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritis
135. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis
136. Clinical and radiological amelioration of refractory peripheral spondylo-arthritis by pulse intravenous pamidronate therapy
137. Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis
138. Thalidomide: A comeback?
139. Thalidomide: Current and potential clinical applications
140. The role of HLA genes in familial spondyloarthropathy: A comprehensive study of 70 multiplex families